Trial Radar KI | ||
|---|---|---|
Die klinische Studie NCT06824103 für Graft vs. Host Disease, Chronic Graft vs. Host Disease, Corticosteroid-refractory Chronic Graft vs. Host Disease ist offene rekrutierung. In der Kartenansicht des Klinische Studien Radar und den KI-Entdeckungstools finden Sie alle Details. Oder stellen Sie hier Ihre Fragen. | ||
Eine Studie entspricht den Filterkriterien
Kartenansicht
Zurück zur Suche
NovartisStudy of Efficacy and Safety of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft vs. Host Disease Phase 4 50 Pädiatrisch
Die Details der klinischen Studie sind hauptsächlich auf Englisch verfügbar. Trial Radar KI kann jedoch helfen! Klicken Sie einfach auf 'Studie erklären', um die Informationen zur Studie in der ausgewählten Sprache anzuzeigen und zu besprechen.
Die klinische Studie NCT06824103 untersucht Behandlung im Zusammenhang mit Graft vs. Host Disease, Chronic Graft vs. Host Disease, Corticosteroid-refractory Chronic Graft vs. Host Disease. Diese interventionsstudie der Phase 4 hat den Status offene rekrutierung und startete am 9. September 2025. Es ist geplant, 50 Teilnehmer aufzunehmen. Durchgeführt von Novartis wird der Abschluss für 11. Januar 2032 erwartet. Die Daten von ClinicalTrials.gov wurden zuletzt am 26. November 2025 aktualisiert.
Kurzbeschreibung
The purpose of the study is to assess the efficacy and safety of ruxolitinib in Chinese adult and pediatric participants aged 12 years or older with corticosteroid-refractory chronic graft vs. host disease (SR-cGvHD).
Ausführliche Beschreibung
This is a single arm, multi-center, open label study which will enroll approximately 50 participants and investigate the efficacy and safety of ruxolitinib administered in adult and adolescent (≥12 years old) Chinese participants with SR-cGvHD.
The total duration on study for an individual participant will be up to 164 weeks (approximately 3 years).
The study consists of following periods, with each cycle comprised...
Mehr anzeigenOffizieller Titel
A Single-arm Multi-center Study of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft Versus Host Disease After Allogeneic Stem Cell Transplantation
Erkrankungen
Graft vs. Host DiseaseChronic Graft vs. Host DiseaseCorticosteroid-refractory Chronic Graft vs. Host DiseaseWeitere Studien-IDs
- CINC424D2413
NCT-Nummer
Studienbeginn (tatsächlich)
2025-09-09
Zuletzt aktualisiert
2025-11-26
Studienende (vorauss.)
2032-01-11
Geplante Rekrutierung
50
Studientyp
Interventionsstudie
PHASE
Phase 4
Status
Offene Rekrutierung
Stichwörter
cGvHD
GvHD
SR-cGvHD
ruxolitinib
INC424
Chinese adult
Pediatric
Corticosteroid
refractory
GvHD
SR-cGvHD
ruxolitinib
INC424
Chinese adult
Pediatric
Corticosteroid
refractory
Primäres Ziel
Behandlung
Zuteilungsmethode
Nicht zutreffend
Interventionsmodell
Einarmige Studie
Verblindung
Keine (offene Studie)
Studienarme/Interventionen
| Teilnehmergruppe/Studienarm | Intervention/Behandlung |
|---|---|
ExperimentellRuxolitinib Chinese participants (adult and pediatric) who will receive ruxolitinib daily. | Ruxolitinib Ruxolitinib is taken orally daily at 10 mg BID, given as two 5 mg tablets. |
Hauptergebnismessungen
Nebenergebnismessungen
| Ergebnismessung | Beschreibung der Messung | Zeitrahmen |
|---|---|---|
Overall Response Rate (ORR) | ORR is defined as the percentage of participants demonstrating a complete response (CR) or partial response (PR) without the requirement of additional systemic therapies for an earlier progression, mixed response or non-response, according to National Institute of Health (NIH) Consensus Criteria. | Cycle 7 Day 1; each Cycle =28 days |
| Ergebnismessung | Beschreibung der Messung | Zeitrahmen |
|---|---|---|
Failure-free Survival (FFS) | FFS is defined as the time from the date of start of study treatment to the earliest of: i) relapse or recurrence of underlying disease or death due to underlying disease, ii) nonrelapse mortality, or iii) addition or initiation of another systemic therapy for cGvHD. | up to 3 years |
Best Overall Response (BOR) | Percentage of participants who achieved overall response (CR+PR) at any time point (up Cycle 7 Day 1 or the start of additional systemic therapy for cGvHD). | at any point up to cycle 7 day 1 (each cycle is 28 days) or the start of additional systemic therapy for cGvHD, approx. 6 months |
ORR at end of cycle 3 | Percentage of participants who achieved overall response (CR+PR) at Cycle 4 Day 1. | end of cycle 3; each cycle = 28 days |
Duration of Response (DOR) | DOR is assessed for responders only and is defined as the time from first response until cGvHD progression, death, or the date of addition of systemic therapies for cGvHD. | from first response until cGvHD progression, death, or the date of addition of systemic therapies for cGvHD, approx.36 months |
Overall Response (OS) | OS is defined as the time from the date of study treatment (ruxolitinib) initiation to the date of death due to any cause. | from the date of study treatment (ruxolitinib) initiation to the date of death due to any cause, approx. 36 months |
Non-Relapse Mortality (NRM) | NRM is defined as the time from date of study treatment (ruxolitinib) initiation to date of death not preceded by underlying disease relapse/recurrence. | from date of study treatment (ruxolitinib) initiation to date of death not preceded by underlying disease relapse/recurrence, approx. 36 months |
Malignancy Relapse/Recurrence (MR) | Malignancy relapse/recurrence is defined as the time from date of study treatment to hematologic malignancy relapse/recurrence. | from date of study treatment to hematologic malignancy relapse/recurrence, approx. 36 months |
Reduction of daily corticosteroids dose at cycle 7 day 1 | Systemic corticosteroid use is the percentage of participants with \>=50% reduction from baseline in daily corticosteroid dose, the proportion of subjects with reduction from baseline to ≤ 0.2 mg/kg/day methylprednisolone (or equivalent dose of ≤ 0.25 g/kg/day prednisone or prednisolone), and subjects successfully tapered off all systemic corticosteroids at Cycle 7 Day 1, by time intervals and overall. | Cycle 7 Day 1; each cycle = 28 days |
Teilnahme-Assistent
Eignungskriterien
Zugelassene Altersgruppen
Kind, Erwachsene, Ältere Erwachsene
Mindestalter
12 Years
Zugelassene Geschlechter
Alle
Signed informed consent must be obtained prior to participation in the study.
Male or female Chinese participants aged 12 or older at the time of informed consent
Able to swallow tablets.- Have undergone alloSCT from any donor source (matched unrelated donor, sibling, haplo-identical) using bone marrow, peripheral blood stem cells, or cord blood. Recipients of non-myeloablative, myeloablative, and reduced intensity conditioning are eligible.
Evident myeloid and platelet engraftment:
- Absolute neutrophil count (ANC) >1,000/mm3 AND
- Platelet count ≥25,000/mm3
Note: Use of growth factor supplementation and transfusion support is allowed during the trial, however, transfusion to reach a minimum platelet count for inclusion is not allowed during screening and at baseline.
Participants with clinically diagnosed cGvHD staging of moderate to severe according to NIH Consensus Criteria (Jagasia et al 2015) prior to Cycle 1 Day 1.
- Moderate cGvHD: at least one organ (not lung) with a score of 2, 3 or more organs involved with a score of 1 in each organ, or lung score of 1.
- Severe cGvHD: at least 1 organ with a score of 3, or lung score of 2 or 3.
Participants currently receiving systemic corticosteroids for the treatment of cGvHD for a duration of < 12 months prior to Cycle 1 Day 1, and have a confirmed diagnosis of corticosteroid refractory cGvHD defined per 2014 NIH consensus criteria (Martin et al 2015) irrespective of the concomitant use of a calcineurin inhibitor, as follows:
- A lack of response or disease progression after administration of minimum prednisone 1 mg/kg/day for at least 1 week (or equivalent) OR
- Disease persistence without improvement despite continued treatment with prednisone at >0.5 mg/kg/day or 1 mg/kg/every other day for at least 4 weeks (or equivalent) OR
- Increase to prednisone dose to >0.25 mg/kg/day after two unsuccessful attempts to taper the dose (or equivalent)
Participants has Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
For a full list of exclusion criteria, refer to Section 5.2. Key exclusion criteria include
- Participants who have received two or more systemic treatments for cGvHD in addition to corticosteroids ± CNI for cGvHD.
- Participants who have received ROCK2 inhibitors for cGvHD.
- Participants that transition from active aGvHD to cGvHD without tapering off corticosteroids ± CNI and any systemic treatment
Note: Participants receiving up to 30 mg by mouth once a day of hydrocortisone (i.e., physiologic replacement dose) of corticosteroids are allowed.
- Participants who were treated with prior JAK inhibitors for aGvHD; except when the participant achieved complete or partial response and has been off JAK inhibitor treatment for at least 8 weeks prior to Cycle 1 Day 1.
- Failed prior alloSCT within the past 6 months from Cycle 1 Day 1.
- Participants with relapsed primary malignancy, or who have been treated for relapse after the alloSCT was performed.
- SR-cGvHD occurring after a non-scheduled donor lymphocyte infusion (DLI) administered for pre-emptive treatment of malignancy recurrence. Participants who have received a scheduled DLI as part of their transplant procedure and not for management of malignancy relapse are eligible.
Other protocol-defined inclusion/exclusion may apply.
NovartisZentrale Studienkontakte
Kontakt: Novartis Pharmaceuticals, +41613241111, [email protected]
Kontakt: Novartis Pharmaceuticals
19 Studienstandorte in 1 Ländern
Anhui
Novartis Investigative Site, Hefei, Anhui, 230001, China
Offene Rekrutierung
Guangdong
Novartis Investigative Site, Guangzhou, Guangdong, 510000, China
Offene Rekrutierung
Novartis Investigative Site, Guangzhou, Guangdong, 510515, China
Offene Rekrutierung
Guangxi
Novartis Investigative Site, Nanning, Guangxi, 530021, China
Offene Rekrutierung
Guizhou
Novartis Investigative Site, Guiyang, Guizhou, 550004, China
Offene Rekrutierung
Hebei
Novartis Investigative Site, Shijiazhuang, Hebei, 050000, China
Offene Rekrutierung
Henan
Novartis Investigative Site, Zhengzhou, Henan, 450003, China
Offene Rekrutierung
Hubei
Novartis Investigative Site, Wuhan, Hubei, 430030, China
Offene Rekrutierung
Jiangsu
Novartis Investigative Site, Nanjing, Jiangsu, 210029, China
Offene Rekrutierung
Jiangxi
Novartis Investigative Site, Nanchang, Jiangxi, 330006, China
Offene Rekrutierung
Sichuan
Novartis Investigative Site, Chengdu, Sichuan, 610041, China
Offene Rekrutierung
Zhejiang
Novartis Investigative Site, Hangzhou, Zhejiang, 310003, China
Offene Rekrutierung
Novartis Investigative Site, Ningbo, Zhejiang, 315016, China
Offene Rekrutierung
Novartis Investigative Site, Wenzhou, Zhejiang, 325000, China
Offene Rekrutierung
Novartis Investigative Site, Beijing, 100034, China
Offene Rekrutierung
Novartis Investigative Site, Beijing, 100070, China
Offene Rekrutierung
Novartis Investigative Site, Changsha, 410000, China
Offene Rekrutierung
Novartis Investigative Site, Shanghai, 200025, China
Offene Rekrutierung
Novartis Investigative Site, Shanhecun, 065201, China
Offene Rekrutierung